However, the association between familial hypercholesterolemia variants and coronary heart disease slightly weakened after adjusting for baseline low-density lipoprotein cholesterol (LDL-C) level and became statistically insignificant after adjusting for cumulative past LDL-C exposure.
An analysis of the DELIVER trial also revealed an association between dapagliflozin treatment and reduced risk of cardiovascular death among individuals with heart failure with improved ejection fraction (HFimpEF).
South Korea: The de-escalation strategy is a reasonable and safe strategy option following myocardial infarction (MI) in patients with high ischemic risk, a recent study published in JAMA Cardiology.
Despite an initial drop in estimated glomerular filtration rate (eGFR) after 1 month of dapagliflozin, researchers say this is not associated with subsequent risk of cardiovascular or kidney events for patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF).